Welcome to our dedicated page for electroCore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on electroCore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
electroCore, Inc. (Nasdaq: ECOR) announced a $6.0 million grant from the National Institute on Drug Abuse for a pivotal clinical trial of its gammaCore nVNS device to treat opioid use disorder (OUD). The trial, to be conducted at Emory University and Georgia Institute of Technology, will enroll approximately 100 patients and evaluate the efficacy of gammaCore in reducing opioid withdrawal symptoms. Dr. Douglas Bremner noted the significance of this research as there are limited effective treatments for OUD. Peter Staats, CMO of electroCore, emphasized the potential of gammaCore to alleviate withdrawal pain and reduce healthcare costs. The study follows promising pilot data highlighting the device's ability to decrease both psychological and physiological withdrawal symptoms.
electroCore (Nasdaq: ECOR) has announced results from a clinical trial that highlights the efficacy of its gammaCore non-invasive vagus nerve stimulation (nVNS) in enhancing second language learning. Conducted at the Defense Language Institute (DLI) and supported by DARPA, the study involved 36 participants learning Arabic. Results showed that those using gammaCore exhibited significantly improved language recall compared to a sham group (p=0.025). Additionally, participants reported enhanced energy (p=0.036) and focus (p=0.001) throughout the training. The trial's findings suggest potential applications for military training and cognitive performance improvement. The study represents a critical advancement for electroCore's nVNS technology, which aims to promote overall wellbeing.
electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine company, will announce its financial results for Q1 2023 on May 3, 2023, after market close. A conference call will be held at 4:30 PM EDT to discuss results and answer questions. The company focuses on non-invasive vagus nerve stimulation (nVNS) technology for managing medical conditions and enhancing wellbeing. electroCore aims to commercialize medical devices and consumer products in the U.S. and selected international markets.